Cao et al. used nivolumab, a PD-1 inhibitor, in combination with CD-19 CAR-T in patients with refractory or relapsed B-cell non-Hodgkin lymphoma, achieving remission in around 45% of patients [121]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.